These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 7511761)

  • 1. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
    Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
    Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
    J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine.
    Damiano BP; Stump GL; Cheung WM; Salata JJ
    J Cardiovasc Pharmacol; 1993 Jul; 22(1):143-52. PubMed ID: 7690086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N
    Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of the novel potassium channel opener (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxo- 1-pyrrolidinyl)-6-phenylsulfonylchromane hemihydrate.
    Linz W; Klaus E; Albus U; Becker R; Mania D; Englert HC; Schölkens BA
    Arzneimittelforschung; 1992 Oct; 42(10):1180-5. PubMed ID: 1472138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
    Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T
    Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
    Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
    Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic and coronary hemodynamic effects of JTV-506, a novel potassium channel opener, in conscious dogs: comparison with cromakalim and nicorandil.
    Zhang S; Sakai K; Hasuo H; Furuta K; Ureshino H; Shibata O; Sumikawa K
    Res Commun Mol Pathol Pharmacol; 1999; 105(1-2):115-27. PubMed ID: 10850375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
    Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
    Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the new dihydropyridine derivative 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester on the cardiohemodynamics and the energy metabolism of ischemic myocardium.
    Imai H; Matsui K; Ochi S; Nakazawa M; Nakagawa Y; Imai S
    Arzneimittelforschung; 1987 Dec; 37(12):1348-52. PubMed ID: 3449062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cardiovascular effects of KRN2391 and other coronary vasodilators in anesthetized open-chest dogs.
    Ogawa N; Kaneta S; Jinno Y; Kasai H; Nishikori K; Fukushima H
    Arch Int Pharmacodyn Ther; 1992; 318():36-46. PubMed ID: 1463370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part I: Respiratory and cardiovascular systems.
    Hirohashi M; Takasuna K; Yamashita N; Tamura K
    Arzneimittelforschung; 1991 Jan; 41(1):9-18. PubMed ID: 1675573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular pharmacological studies on JTV-506, a new potassium channel opener. 1st communication: effects on myocardium and vasculature.
    Hirata Y; Suzuki Y; Miyai H; Aisaka K
    Arzneimittelforschung; 2000 Mar; 50(3):236-43. PubMed ID: 10758774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of nicardipine hydrochloride in anesthetized dogs with acute heart failure. Part 1: Hemodynamic effects in normal dogs and dogs with acute heart failure.
    Saitoh C; Momose K; Tanaka H; Sato S; Taguchi K; Saitoh M; Maehara J; Asano M; Usuda S
    Arzneimittelforschung; 1998 Feb; 48(2):125-32. PubMed ID: 9541721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary blood flow and myocardial oxygen consumption after alpha adrenergic blockade during submaximal exercise.
    Gwirtz PA; Stone HL
    J Pharmacol Exp Ther; 1981 Apr; 217(1):92-8. PubMed ID: 6110777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anesthetized dogs.
    Imamoto T; Tanabe M; Shimamoto N; Kawazoe K; Hirata M
    Arzneimittelforschung; 1984; 34(2):161-9. PubMed ID: 6539108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of the K-ATP channel blocker U-37883A and structurally related morpholinoguanidines.
    Humphrey SJ; Smith MP; Cimini MG; Buchanan LV; Gibson JK; Khan SA; Meisheri KD
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):247-60. PubMed ID: 8803957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the new nitrate ester ITF 296 on coronary and systemic hemodynamics in the conscious dog: comparison with nitroglycerin and nicorandil.
    Ueno A; Bergamaschi M; Gromo G; Nonaka K; Mizrahi J
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S13-20. PubMed ID: 8839221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes.
    Auchampach JA; Maruyama M; Cavero I; Gross GJ
    J Pharmacol Exp Ther; 1991 Dec; 259(3):961-7. PubMed ID: 1762089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dose-dependent effect of amrinone on hemodynamics, myocardial circulation and myocardial energy requirement. An experimental study].
    Veit S; Brückner JB; Vogt K; Wagner R; Hess W
    Z Kardiol; 1985 Feb; 74(2):76-84. PubMed ID: 3993153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.